DIANTHUS THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.69 USD | -0.89% |
|
+14.00% | +166.25% |
| 05-16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
| 05-10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 154.1 | 752.2 | - | - |
| Enterprise Value (EV) 1 | 154.1 | 438.7 | 233.7 | 752.2 |
| P/E ratio | -1.23 x | -11.7 x | -9.85 x | -7.88 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 54.5 x | 412 x | 380 x | 278 x |
| EV / Revenue | 54.5 x | 241 x | 118 x | 278 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | -5.62 x | -2.73 x | -7.66 x |
| FCF Yield | - | -17.8% | -36.7% | -13.1% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 14,818 | 29,349 | - | - |
| Reference price 2 | 10.40 | 25.63 | 25.63 | 25.63 |
| Announcement Date | 24-03-21 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 2.826 | 1.824 | 1.977 | 2.707 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -48.17 | -77.53 | -97.8 | -130 |
| Operating Margin | - | -1,704.67% | -4,251.55% | -4,945.61% | -4,802.42% |
| Earnings before Tax (EBT) 1 | - | -43.56 | -63.65 | -88.36 | -120.8 |
| Net income 1 | -28.48 | -43.56 | -63.65 | -88.36 | -120.8 |
| Net margin | - | -1,541.22% | -3,490.48% | -4,468.65% | -4,462.44% |
| EPS 2 | -7.100 | -8.450 | -2.193 | -2.601 | -3.252 |
| Free Cash Flow 1 | - | - | -78 | -85.74 | -98.21 |
| FCF margin | - | - | -4,277.09% | -4,335.68% | -3,627.88% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 23-08-01 | 24-03-21 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.924 | 0.457 | 0.874 | 0.3137 | 0.3137 | 0.3137 | 0.319 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -15.76 | -12.96 | -17.84 | -18.56 | -19.88 | -21.26 | -18.91 |
| Operating Margin | -1,705.52% | -2,835.01% | -2,041.65% | -5,917.74% | -6,338.14% | -6,778.46% | -5,927.43% |
| Earnings before Tax (EBT) 1 | -14.76 | -10.56 | -13.75 | -14.95 | -16.33 | -18.64 | -15.63 |
| Net income 1 | -14.76 | -10.56 | -13.75 | -14.95 | -16.33 | -18.64 | -15.63 |
| Net margin | -1,597.73% | -2,311.38% | -1,573% | -4,766.47% | -5,206.43% | -5,942.76% | -4,898.43% |
| EPS 2 | -3.780 | - | -0.5400 | -0.5317 | -0.5767 | -0.6317 | -0.5500 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 23-11-09 | 24-03-21 | 24-05-09 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 314 | 519 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -78 | -85.7 | -98.2 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 0.13 | 0.18 | 0.21 |
| Capex / Sales | - | - | 7.02% | 9.31% | 7.7% |
| Announcement Date | 23-08-01 | 24-03-21 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
25.63
USD
Average target price
49.29
USD
Spread / Average Target
+92.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +166.25% | 752M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- DNTH Stock
- Financials Dianthus Therapeutics, Inc.
